NIZATIDINE, AN H-2-BLOCKER - ITS METABOLISM AND DISPOSITION IN MAN
- 1 March 1986
- journal article
- research article
- Vol. 14 (2) , 175-182
Abstract
The disposition of a single oral dose of about 150 mg of nizatidine, an H2-blocker, was studied in five men. Plasma levels of both parent drug and radioactivity peaked in 1-3 hr. Nizatidine accounted for about 60% of the plasma radioactivity. The t1/2 of nizatidine was 1.6 hr. About 35% of nizatidine became bound to plasma proteins in vitro, particularly to .alpha.-1-glycoprotein. Warfarin, acetaminophen, phenobarbital, propantheline, diazepam, and propranolol did not notably affect the amount of nizatidine bound. Two to 3 times more radioactivity was in plasma than in blood cells or saliva. Greater than 90% of the dose of nizatidine was excreted in urine, probably by glomerular filtration and active tubular secretion. Nizatidine accounted for about 65% of the urinary radioactivity. The major metabolite of nizatidine was N2-monodesmethylnizatidine; it represented about 7% of the nizatidine dosage. Another metabolite, constituting about 5% of the dose, is proposed to be nizatidine N2-oxide. Nizatidine sulfoxide also may be a minor metabolite of nizatidine.This publication has 8 references indexed in Scilit:
- Intravenous nizatidine kinetics and acid suppressionClinical Pharmacology & Therapeutics, 1985
- Cimetidine inhibits renal procainamide clearanceClinical Pharmacology & Therapeutics, 1984
- Physiologic disposition of pergolideClinical Pharmacology & Therapeutics, 1981
- DISPOSITION OF L-3-[(DIMETHYLAMINO)-(M-DIOXAN-5-YL)METHYL]PYRIDINE IN MAN1979
- Physiologic disposition of nabilone, a cannabinol derivative, in manClinical Pharmacology & Therapeutics, 1977
- METABOLISM AND ELIMINATION OF CIMETIDINE, A HISTAMINE H2-RECEPTOR ANTAGONIST, IN RAT, DOG, AND MAN1977
- PLASMA-PROTEIN BINDING OF BASIC DRUGS .1. SELECTIVE DISPLACEMENT FROM ALPHA1-ACID GLYCOPROTEIN BY TRIS(2-BUTOXYETHYL) PHOSPHATE1977
- Aminopyrine demethylation measured by breath analysis in cirrhosisClinical Pharmacology & Therapeutics, 1976